Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the pancreas meeting 1 of the following criteria:
• * Newly diagnosed or previously treated metastatic disease
• * Unresectable disease
• No CNS or brain metastases
• PATIENT CHARACTERISTICS:
• Age
• Over 18
• Performance status
• ECOG 0-1
• Life expectancy
• More than 3 months
• Hematopoietic
• Absolute neutrophil count \> 1,500/mm\^3
• WBC \> 3,000/mm\^3
• Platelet count \> 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
• No evidence of bleeding diathesis or coagulopathy
• Hepatic
• Bilirubin \< 2 mg/dL
• AST or ALT \< 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
• INR \< 1.5 (except for patients receiving full-dose warfarin)
• Renal
• Creatinine \< 1.5 mg/dL
• No proteinuria OR
• Urine protein \< 500 mg by 24-hour urine collection
• No clinically significant impairment of renal function
• Cardiovascular
• No uncontrolled hypertension (blood pressure \> 160/110 mm Hg on medication)
• No New York Heart Association class II-IV congestive heart failure
• No unstable symptomatic arrhythmia requiring medication
• * Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
• No clinically significant grade II-IV peripheral vascular disease
• No arterial thromboembolic event within the past 6 months, including any of the following:
• * Transient ischemic attack
• * Cerebrovascular accident
• * Unstable angina
• * Myocardial infarction
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other serious systemic disease
• No significant traumatic injury within the past 28 days
• No serious non-healing wound, ulcer, or bone fracture
• No history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• More than 28 days since prior major surgery or open biopsy
• More than 7 days since prior fine needle aspirations or core biopsies
• No concurrent major surgery
• Other
• More than 4 weeks since prior and no concurrent participation in any other experimental drug study
• More than 12 months since prior adjuvant therapy
• No prior systemic therapy for metastatic disease